RotaTeq™ experimental formulation + RotaTeq™ existing formulation

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rotavirus Gastroenteritis

Conditions

Rotavirus Gastroenteritis

Trial Timeline

Apr 29, 2013 → Mar 25, 2014

About RotaTeq™ experimental formulation + RotaTeq™ existing formulation

RotaTeq™ experimental formulation + RotaTeq™ existing formulation is a phase 3 stage product being developed by Merck for Rotavirus Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01600092. Target conditions include Rotavirus Gastroenteritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01600092Phase 3Completed